Published in Int J Mol Sci on August 27, 2016
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer | NCT00036543
Bone metastasis risk factors in breast cancer. Ecancermedicalscience (2017) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Osteoclast differentiation and activation. Nature (2003) 18.59
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med (1996) 5.87
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Skeletal complications of malignancy. Cancer (1997) 5.41
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2015) 4.58
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Tumour exosome integrins determine organotropic metastasis. Nature (2015) 4.09
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol (2014) 3.40
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Genes associated with breast cancer metastatic to bone. J Clin Oncol (2006) 3.21
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res (2006) 2.67
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res (2010) 2.62
Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res (2005) 2.59
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol (2014) 2.31
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Mechanisms of bone metastasis. Cancer (1997) 2.29
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell (2015) 1.91
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging (2010) 1.69
Two hundred years of cancer research. N Engl J Med (2012) 1.69
The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev (2006) 1.69
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol (2013) 1.68
Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal (2005) 1.65
Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate (2007) 1.56
Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res (2012) 1.55
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol (2009) 1.44
Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol (2011) 1.41
Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer (2010) 1.33
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev (2012) 1.32
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest (2002) 1.13
New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol (2012) 1.10
Pathogenesis of myeloma bone disease. J Cell Biochem (2010) 1.06
GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One (2013) 1.06
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. J Natl Cancer Inst (2015) 0.97
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol (2015) 0.95
The prostate cancer bone marrow niche: more than just 'fertile soil'. Asian J Androl (2012) 0.92
Distinctive properties of metastasis-initiating cells. Genes Dev (2016) 0.91
Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat (2014) 0.90
Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol (1992) 0.88
Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. J Mol Histol (2012) 0.88
Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis (2011) 0.87
Molecular Mechanisms of Bone Metastasis. Cancer Genomics Proteomics (2015) 0.87
Genetics of breast cancer bone metastasis: a sequential multistep pattern. Clin Exp Metastasis (2014) 0.87
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin Breast Cancer (2009) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone (1987) 0.86
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol (2010) 0.86
Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. Eur Urol (2015) 0.85
Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep (2013) 0.83
Tumour-derived miRNAs and bone metastasis. Bonekey Rep (2015) 0.83
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. J Natl Cancer Inst (2016) 0.82
The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett (2015) 0.80
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev (2016) 0.79
The Bone Microenvironment: a Fertile Soil for Tumor Growth. Curr Osteoporos Rep (2016) 0.78
Adjuvant Bisphosphonates and Breast Cancer Survival. Annu Rev Med (2015) 0.78